Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium

European Journal of Pharmaceutical Sciences

Volumn 51, Issue 1, 2014, Pages 204-210

  Borkar, Nrupa ^a   Xia, Dengning ^a,b,c   Holm, René ^a,d   Gan, Yong ^b   Müllertz, Anette ^a   Yang, Mingshi ^a   Mu, Huiling ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^c SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^d H LUNDBECK A S   (Denmark)

Author keywords

Absorption; Fenofibrate; In vitro lipolysis; Lipid matrix particle; Particle size

Indexed keywords

CLOFIBRIC ACID; DRUG CARRIER; FENOFIBRATE; LIPID; LIPID MATRIX PARTICLE; PANCREATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; MALE; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

4-BROMOBENZENEBORONIC ACID; ABSORPTION; ANALYSIS OF VARIANCE; ANOVA; AREA UNDER CURVE; AUC; BBBA; C(MAX); FENOFIBRATE; FFAS; FREE FATTY ACIDS; GASTRO-INTESTINAL TRACT; GIT; GLYCERYL MONOSTEARATE; GMS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC; HPMC; HYDROXY PROPYL METHYLCELLULOSE; IN VITRO LIPOLYSIS; IN VITRO-IN VIVO CORRELATION; IVIVC; LIPID MATRIX PARTICLE; LIPID MATRIX PARTICLES; LMP; MAXIMAL PLASMA CONCENTRATION; MCT; MEDIUM CHAIN TRIGLYCERIDE; PARTICLE SIZE; SDS; SELF NANO-EMULSIFYING DRUG DELIVERY SYSTEMS; SEM; SNEDDS; SODIUM DODECYL SULFATE; STANDARD ERROR OF MEAN; T(MAX); TIME REQUIRED FOR MAXIMAL PLASMA CONCENTRATION; UNITED STATES PHARMACOPEIA; USP;

ABSORPTION; ANIMALS; AREA UNDER CURVE; FENOFIBRATE; LIPIDS; LIPOLYSIS; MALE; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; WATER;

EID: 84886545604     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.09.022     Document Type: Article

References (33)

1. S.T. Buckley, K.J. Frank, G. Fricker, and M. Brandl Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations" Eur. J. Pharm. Sci. 50 2013 8 16
2. C.M. Carey, M.D. Small, and M.C. Bliss Lipid digestion and absorption Annu. Rev. Physiol. 45 1983 651 677
3. Y. Chen, Y. Lu, J. Chen, J. Lai, J. Sun, F. Hu, and W. Wu Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt Int. J. Pharm. 376 2009 153 160
4. J.F. Cuiné, C.L. McEvoy, W.N. Charman, C.W. Pouton, G.A. Edwards, H. Benameur, and C.J.H. Porter Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs J. Pharm. Sci. 97 2008 995 1012 (Pubitemid 351293898)
5. A. Dahan, and A. Hoffman Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs J. Control. Release 129 2008 1 10
6. P. Ekambaram, and H.S. Abdul Formulation and evaluation of solid lipid nanoparticles of ramipril J. Young Pharm. 3 2011 216 220
7. K.J. Frank, U. Westedt, K.M. Rosenblatt, P. Holig, J. Rosenberg, M. Magerlein, M. Brandl, and G. Fricker Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound Eur. J. Pharm. Sci. 47 2012 16 20
8. A. Hanafy, H. Spahn-Langguth, G. Vergnault, P. Grenier, M. Tubic Grozdanis, T. Lenhardt, and P. Langguth Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug Adv. Drug Deliv. Rev. 59 2007 419 426 (Pubitemid 47260709)
9. R. Holm, A. Müllertz, and H. Mu Bile salts and their importance for drug absorption Int. J. Pharm. 453 2013 44 55
10. L. Hu, X. Tang, and F. Cui Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs J. Pharm. Pharmacol. 56 2004 1527 1535 (Pubitemid 39601993)
11. L. Hu, H. Wu, F. Niu, C. Yan, X. Yang, and Y. Jia Design of fenofibrate microemulsion for improved bioavailability Int. J. Pharm. 420 2011 251 255
12. J.B. Jeevana, and K. Sreelakshmi Design and evaluation of self-nanoemulsifying drug delivery system of flutamide J. Young Pharm. 3 2011 4 8
13. A.T. Larsen, P. Sassene, and A. Mullertz In vitro lipolysis models as a tool for the characterization of oral lipid and surfactant based drug delivery systems Int. J. Pharm. 417 2011 245 255
14. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 2000 235 249 (Pubitemid 32239479)
15. K. Mohsin, M.A. Long, and C.W. Pouton Design of lipid-based formulations for oral administration of poorly water-soluble drugs: Precipitation of drug after dispersion of formulations in aqueous solution J. Pharm. Sci. 98 2009 3582 3595
16. H. Mu, R. Holm, and A. Müllertz Lipid-based formulations for oral administration of poorly water-soluble drugs Int. J. Pharm. 453 2013 215 224
17. M. Muchow, P. Maincent, and R.H. Müller Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery Drug Dev. Ind. Pharm. 34 2008 1394 1405
18. R. Müller, K. Mäder, and S. Gohla Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art Eur. J. Pharm. Biopharm. 50 2000 161 177 (Pubitemid 30326695)
19. R.H. Müller, M. Radtke, and S.A. Wissing Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations Adv. Drug Del. Rev. 54 2002 S131 S155
20. R.H. Müller, S.A. Runge, V. Ravelli, A.F. Thunemann, W. Mehnert, and E.B. Souto Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation Eur. J. Pharm. Biopharm. 68 2008 535 544 (Pubitemid 351318197)
21. G. Nicolaos, S. Crauste-Manciet, R. Farinotti, and D. Brossard Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion Int. J. Pharm. 263 2003 165 171 (Pubitemid 37087943)
22. C.J. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 6 2007 231 248 (Pubitemid 46344627)
23. C.J.H. Porter, A.M. Kaukonen, A. Taillardat-Bertschinger, B.J. Boyd, J.M. O'Connor, G.A. Edwards, and W.N. Charman Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine J. Pharm. Sci. 93 2004 1110 1121 (Pubitemid 38529685)
24. S. Ren, H. Mu, F. Alchaer, A. Chtatou, and A. Mullertz Optimization of self nanoemulsifying drug delivery system for poorly water-soluble drug using response surface methodology Drug Dev. Ind. Pharm. 39 2013 799 806
25. A. Sharma, M. Jindal, G. Aggarwal, and S. Jain Development of a novel method for fabrication of solid lipid nanoparticles: using high shear homogenization and ultrasonication Res. J. Pharm. Biol. Chem. Sci. 1 2010 265 274
26. E.B. Souto, and R.H. Müller Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes Handb. Exp. Pharmacol. 2010 115 141
27. H. Thakkar, J. Nangesh, M. Parmar, and D. Patel Formulation and characterization of lipid-based drug delivery system of raloxifene-microemulsion and self-microemulsifying drug delivery system J. Pharm. Bioallied Sci. 3 2011 442 448
28. R. Tiwari, and K. Pathak Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake Int. J. Pharm. 415 2011 232 243
29. K. Westesen, H. Bunjes, and M.H.J. Koch Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential J. Control. Release 48 1997 223 236 (Pubitemid 27401980)
30. S. Xie, L. Zhu, Z. Dong, Y. Wang, X. Wang, and W. Zhou Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles Int. J. Nanomed. 6 2011 547 555
31. N. Zangenberg, A. Müllertz, H. Kristensen, and L. Hovgaard A dynamic in vitro lipolysis model: II. Evaluation of the model Eur. J. Pharm. Sci. 14 2001 237 244 (Pubitemid 32884320)
32. N.M.A. Zangenberg, and H.H.L. Kristensen A dynamic in vitro lipolysis model: I. Controlling the rate of lipolysis by continuous addition of calcium Eur. J. Pharm. Sci. 14 2001 115 122
33. A. Zur Mühlen, C. Schwarz, and W. Mehnert Solid lipid nanoparticles (SLN) for controlled drug delivery -Drug release and release mechanism Eur. J. Pharm. Biopharm. 45 1998 149 155 (Pubitemid 28167741)